Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: xcr600 who wrote (8413)	6/10/2002 2:56:15 PM
From: Bucky Katt	Respond to of 48461

No idea on ROYL right now, it seems overpriced based on gas/oil futures, so I would be interested on a break under 4 bucks.

To: xcr600 who wrote (8413)	6/12/2002 11:00:49 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 48461

Anyone remember this about SEBL from 5 June? In another vein, I remember a few months ago, when SEBL was a bit of a hotter stock than it is now, the ceo, said in every magazine that he could find that their vaunted software was predicting increasing sales just around the corner. I think his software needs some "tweaking" to say the least.http://www.siliconinvestor.com/readmsg.aspx?msgid=17559856 That was ratspeak for a "sell" rating :-> The stock is gettin' "tweaked" today.. Check out the 15 17.5 & 20 June puts today....SWEET! quote.cboe.com Another win for the good guys..... Nice to see they arrested that prick from ImClone today on insider trading. The outcome needs to be jail time, for all involved, even gasp! Martha Stewart!! NEW YORK (Reuters) - Samuel Waksal, the former chief executive of ImClone Systems Inc. (NasdaqNM:IMCL - News), was charged in a criminal complaint unsealed on Wednesday accusing him of conspiracy, securities fraud and perjury involving an insider trading scheme. Waksal, who was arrested early on Wednesday morning, is expected to be presented in Manhattan federal court later in the day, according to federal prosecutors. The insider trading scheme alleged in the complaint involves trading on a tip that the FDA would refuse to allow the experimental cancer drug Erbitux to reach the market.